Structure Therapeutics

Structure Therapeutics has completed enrollment for ACCESS and ACCESS II trials evaluating aleniglipron in obesity treatment, with topline data expected by end of 2025.

• Schrödinger expands collaboration with Otsuka Pharmaceutical and anticipates $150 million upfront payment from Novartis in Q1 2025. • The company plans to present initial Phase 1 data for SGR-1505, SGR-2921, and SGR-3515 in 2025, targeting various cancers. • Schrödinger's co-founded companies, including Ajax, Nimbus, and Structure Therapeutics, reported significant clinical and financial progress in 2024.

Altimmune's pemvidutide, currently in Phase II trials for obesity and metabolic dysfunction-associated steatohepatitis, is projected to reach $1.21 billion in sales by 2030.

Merck & Co. has secured global rights outside China to Hansoh Pharma's preclinical oral GLP-1 receptor agonist for obesity treatment through a $112 million upfront payment.

Structure Therapeutics has selected ACCG-2671, an oral small molecule amylin receptor agonist, as its lead drug candidate for obesity treatment.

• Structure Therapeutics initiates Phase 2b ACCESS trial to evaluate GSBR-1290, an oral GLP-1 receptor agonist, for obesity or overweight with comorbidities. • The ACCESS study will assess multiple doses of GSBR-1290 up to 120 mg over 36 weeks, using a 'low and slow' titration regimen for improved tolerability. • A parallel Phase 2 ACCESS II study will evaluate higher doses (180 and 240 mg) of GSBR-1290, with topline data from both trials expected in Q4 2025. • GSBR-1290 offers potential manufacturing advantages over peptide-based GLP-1R therapies, according to Structure Therapeutics' CEO.

Structure Therapeutics initiates Phase 2b ACCESS trial for GSBR-1290, an oral GLP-1 receptor agonist, to treat obesity.

• Septerna successfully completed an upsized IPO raising $288 million, selling 16 million shares at $18 each, demonstrating strong investor confidence in clinical-stage biotech companies. • The company's lead drug candidate SEP-786, targeting hypoparathyroidism, recently entered Phase 1 clinical trials with data expected by mid-2025. • Septerna plans to allocate $117 million of the proceeds to advance SEP-786 and $37 million for developing SEP-631 for chronic spontaneous urticaria and mast cell conditions.

Novo Nordisk's experimental oral obesity drug amycretin demonstrated 13% weight reduction in just 12 weeks during a small Phase 1 trial, potentially outperforming injectable GLP-1 medications like Wegovy.